A-beta oligomer-PrP-C binding inhibitors (AstraZeneca)

N/A

Report date: 2025/02/01 20:00:06
NME

Base Information

Drug NameA-beta oligomer-PrP-C binding inhibitors (AstraZeneca)
Drug Alias Namebeta-amyloid oligomer-cellular prion protein binding inhibitors (AstraZeneca)beta-amyloid oligomer-cellular prion protein binding inhibitors (Axerion)A-beta oligomer-PrP-C binding inhibitors (Axerion)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionBeta amyloid A4 protein inhibitorsMajor prion protein inhibitors
TargetsBeta amyloid A4 proteinMajor prion protein
Therapy Area/IndicationsAlzheimer Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesYale University
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesYale UniversityAstrazeneca PlcRenetx Bio Inc
Active IndicationsN/A
Inactive IndicationsAlzheimer Disease

Other Information

ATC CodeN/A
Related LinksN/A